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Introduction
Recently Temozolomide (TMZ) has become the more commonly 
used analog of DTIC-related oral agents. Although the response 
rates achieved by TMZ alone are less than satisfactory, there is great 
interest in identifying compounds that could be used in combination 
therapy. We have previously demonstrated that the bioflavonoid 
quercetin (Qct) promotes a p53-mediated response in melanoma and 
sensitizes melanoma to DTIC. Here we demonstrate that Qct also 
sensitizes cells to TMZ by a mechanism that involves the modulation 
of a truncated p53 family member, ΔNp73.
Methods
DB-1 (p53 wild type), and SK Mel 28 (p53 mutant) human melanoma 
cell lines were treated with TMZ (400 μM) for 48 hr followed by 
exposure to Qct (75 μM) for 24 hr. Cell death was determined by 
Annexin V-FITC staining, and immunocytochemical analysis was 
carried out to determine protein translocation.
Results
After treatment with TMZ, DB-1 cells demonstrated increased 
phosphorylation of mutated ATM and p53. However, the cells were 
resistant to TMZ-induced apoptosis and the resistance was associated 
with an increase in nuclear localization of ΔNp73. Qct treatment 
in combination with TMZ abolished drug insensitivity and caused 
a more than additive induction of apoptosis compared to either 
treatment alone. Treatment with Qct caused redistribution of ΔNp73 
into both the cytoplasm and nucleus, which has been associated 
with increased p53 transcriptional activity. Knockdown of ΔNp73 
restored PARP cleavage in the TMZ treated cells, confirming its anti-
apoptotic role. The response to treatment was predominantly p53 
mediated, as the p53 mutant SK Mel 28 cells did not show significant 
enhancement of apoptosis.
Conclusion
This study demonstrates that Qct can sensitize cells to TMZ and 
that the mechanisms of sensitization involve modulation of p53 
family members. These results strongly suggest combination with 
hyperthermia in this treatment scheme. The inhibition of heat-
induced p53/HSF1 by inhibiting p53 would diminish HSP70 levels 
thereby enhancing the heat sensitization of DNA-damage induced 
cell death [Sharma A, et al. Cancer Sci. 2010 Jan 28. Epub ahead of print]. 
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